Research programme: factor Xa inhibitors - Bayer Healthare Pharmaceuticals
Alternative Names: ZK 810388; ZK 814048; ZX 813039Latest Information Update: 24 Mar 2010
At a glance
- Originator Berlex Biosciences
- Class Small molecules
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 18 Sep 2007 Lead development is ongoing
- 04 Apr 2007 Berlex is now called Bayer HealthCare Pharmaceuticals
- 19 Apr 2001 New profile